Cell Therapy for Parkinson’s Disease

In Parkinson’s disease (PD), dopamine neurons in the substantia nigra are degenerated and lost. Cell therapy for PD replaces the lost dopamine neurons by transplanting donor dopamine neural progenitor cells. Cell therapy for PD has been performed in the clinic since the 1980s and uses donor cells fr...

Descripción completa

Detalles Bibliográficos
Autores principales: MORIZANE, Asuka, TAKAHASHI, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japan Neurosurgical Society 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791304/
https://www.ncbi.nlm.nih.gov/pubmed/26912295
http://dx.doi.org/10.2176/nmc.ra.2015-0303
_version_ 1782421066136682496
author MORIZANE, Asuka
TAKAHASHI, Jun
author_facet MORIZANE, Asuka
TAKAHASHI, Jun
author_sort MORIZANE, Asuka
collection PubMed
description In Parkinson’s disease (PD), dopamine neurons in the substantia nigra are degenerated and lost. Cell therapy for PD replaces the lost dopamine neurons by transplanting donor dopamine neural progenitor cells. Cell therapy for PD has been performed in the clinic since the 1980s and uses donor cells from the mesencephalon of aborted embryos. Regenerative medicine for PD using induced pluripotent stem (iPS) cell technology is drawing attention, because it offers a limitless and more advantageous source of donor cells than aborted embryos.
format Online
Article
Text
id pubmed-4791304
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Japan Neurosurgical Society
record_format MEDLINE/PubMed
spelling pubmed-47913042016-03-18 Cell Therapy for Parkinson’s Disease MORIZANE, Asuka TAKAHASHI, Jun Neurol Med Chir (Tokyo) Review Article In Parkinson’s disease (PD), dopamine neurons in the substantia nigra are degenerated and lost. Cell therapy for PD replaces the lost dopamine neurons by transplanting donor dopamine neural progenitor cells. Cell therapy for PD has been performed in the clinic since the 1980s and uses donor cells from the mesencephalon of aborted embryos. Regenerative medicine for PD using induced pluripotent stem (iPS) cell technology is drawing attention, because it offers a limitless and more advantageous source of donor cells than aborted embryos. The Japan Neurosurgical Society 2016-03 2016-02-25 /pmc/articles/PMC4791304/ /pubmed/26912295 http://dx.doi.org/10.2176/nmc.ra.2015-0303 Text en © 2016 The Japan Neurosurgical Society This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Review Article
MORIZANE, Asuka
TAKAHASHI, Jun
Cell Therapy for Parkinson’s Disease
title Cell Therapy for Parkinson’s Disease
title_full Cell Therapy for Parkinson’s Disease
title_fullStr Cell Therapy for Parkinson’s Disease
title_full_unstemmed Cell Therapy for Parkinson’s Disease
title_short Cell Therapy for Parkinson’s Disease
title_sort cell therapy for parkinson’s disease
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791304/
https://www.ncbi.nlm.nih.gov/pubmed/26912295
http://dx.doi.org/10.2176/nmc.ra.2015-0303
work_keys_str_mv AT morizaneasuka celltherapyforparkinsonsdisease
AT takahashijun celltherapyforparkinsonsdisease

Ejemplares similares